GlycoMimetics Agrees to Be Acquired by Crescent Biopharma; Shares Jump

MT Newswires Live10-29

GlycoMimetics' (GLYC) shares climbed by more than 125% early Tuesday after saying it has agreed to be acquired by Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics.

Under the deal, a syndicate of investors has committed $200 million to buy GlycoMimetics common stock and pre-funded warrants, the company said.

The transaction is expected to close in the second quarter of 2025, after which GlycoMimetics will operate under the name Crescent Biopharma, the company said.

GlycoMimetics stockholders are expected to own about 3.1% of the combined company, with the pre-acquisition Crescent shareholders owning the rest, GlycoMimetics said.

Price: 0.3842, Change: +0.22, Percent Change: +128.42

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479288282?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-29 21:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479288282","market":"hk","top_or_hot":-1,"title":"GlycoMimetics Agrees to Be Acquired by Crescent Biopharma; Shares Jump","media":"MT Newswires Live","content":"<html><body><p> GlycoMimetics' (GLYC) shares climbed by more than 125% early Tuesday after saying it has agreed to be acquired by Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics.</p><p>Under the deal, a syndicate of investors has committed $200 million to buy GlycoMimetics common stock and pre-funded warrants, the company said.</p><p>The transaction is expected to close in the second quarter of 2025, after which GlycoMimetics will operate under the name Crescent Biopharma, the company said.</p><p>GlycoMimetics stockholders are expected to own about 3.1% of the combined company, with the pre-acquisition Crescent shareholders owning the rest, GlycoMimetics said.</p><p>Price: 0.3842, Change: +0.22, Percent Change: +128.42</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GlycoMimetics Agrees to Be Acquired by Crescent Biopharma; Shares Jump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlycoMimetics Agrees to Be Acquired by Crescent Biopharma; Shares Jump\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-29 21:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>GlycoMimetics' (GLYC) shares climbed by more than 125% early Tuesday after saying it has agreed to be acquired by Crescent Biopharma, a privately held biotechnology company advancing a pipeline of ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2479288282","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479288282","pubTimestamp":1730209488,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"GlycoMimetics'  shares climbed by more than 125% early Tuesday after saying it has agreed to be acquired by Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics.Under the deal, a syndicate of investors has committed $200 million to buy GlycoMimetics common stock and pre-funded warrants, the company said.The transaction is expected to close in the second quarter of 2025, after which GlycoMimetics will operate under the name Crescent Biopharma, the company said.GlycoMimetics stockholders are expected to own about 3.1% of the combined company, with the pre-acquisition Crescent shareholders owning the rest, GlycoMimetics said.Price: 0.3842, Change: +0.22, Percent Change: +128.42","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GLYC":"GlycoMimetics Inc."},"translate_title":"GlycoMimetics同意被Crescent Biopharma收购；股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLYC":1},"content_text":"GlycoMimetics' (GLYC) shares climbed by more than 125% early Tuesday after saying it has agreed to be acquired by Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics.Under the deal, a syndicate of investors has committed $200 million to buy GlycoMimetics common stock and pre-funded warrants, the company said.The transaction is expected to close in the second quarter of 2025, after which GlycoMimetics will operate under the name Crescent Biopharma, the company said.GlycoMimetics stockholders are expected to own about 3.1% of the combined company, with the pre-acquisition Crescent shareholders owning the rest, GlycoMimetics said.Price: 0.3842, Change: +0.22, Percent Change: +128.42","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479288282"}